Search

- Nov 16
BMO's Evan Seigerman joins Analyst Thursdays from London
Evan Seigerman discusses news from #AHA23, what's going on with Structure, Verve's polarizing result, Neurocrine, Vertex, Pfizer and more.

- Aug 31
BMO Capital Markets’ Evan Seigerman joins BiotechTV for Analyst Thursdays
Evan Seigerman gives his take on biotech and the CMS list, Lilly, Amgen, Skyscraper-01, Structure Therapeutics, Disc Medicine and Replimune.